Kairos Pharma | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings

2025.11.14 18:43

I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.07.

EBIT: As of FY2025 Q3, the actual value is USD -1.472 M.

No revenue was recorded from any sources during the nine months ended September 30, 2025 and 2024.

Net Loss: The net loss for the nine months ended September 30, 2025 was - $4,082, compared to - $1,623 for the same period in 2024.
Operating Expenses: Total operating expenses for the nine months ended September 30, 2025 were $4,157, compared to $897 for the same period in 2024.
Research and Development Expenses: R&D expenses were $1,597 for the nine months ended September 30, 2025, compared to $242 for the same period in 2024.
General and Administrative Expenses: G&A expenses were $2,560 for the nine months ended September 30, 2025, compared to $655 for the same period in 2024.

Operating Cash Flow: Net cash used in operating activities was - $2,357 for the nine months ended September 30, 2025, compared to - $2,152 for the same period in 2024.
Financing Activities: Net cash provided by financing activities was $6,660 for the nine months ended September 30, 2025, compared to $5,276 for the same period in 2024.

Vendor Advances Amortization Expense: Amortization expense relating to vendor advances was $1,958 for the nine months ended September 30, 2025.

Core Business Focus: The company expects its current cash reserves to fund operations for at least 12 months from the date of this filing.
Non-Core Business: The company has entered into various agreements, including an ELOC agreement with Helena Global Investment Opportunities I LTD, which allows the company to issue and sell up to $30,000 of common stock.
Priority: The company will need substantial additional funding to support its continuing operations and pursue its growth strategy, primarily through public or private equity offerings and debt financings.